New Haven drug developer Achillion Pharmaceuticals Inc. says it reaped an extra $8 million from its latest equity offering, money to help it continue refining treatments for acute hepatitis and other blood-borne ailments.
Achillion said its equity underwriters sold an extra 1.44 million shares at $5.90 apiece in a public offering of stock totaling 11.04 million shares. The offering closed Monday.
The company said net proceeds, after underwriting expenses and fees, was $60.9 million,
Bank of America Merrill Lynch and Leerink Swann LLC acted as joint book-running managers for the offering.
ADVERTISEMENT
At mid-morning Tuesday, Achillion shares were up 27 cents, or 3.7 percent, at $7.57.
